Skip to main content

Table 2 Detection of ANA and anti-dsDNA autoantibodies during infliximab treatment

From: Infliximab therapy in rheumatoid arthritis and ankylosing spondylitis-induced specific antinuclear and antiphospholipid autoantibodies without autoimmune clinical manifestations: a two-year prospective study

 

Number of positive sera

ANA

Anti-dsDNA autoantibodies

Infliximab RA (n = 24)

n 0

9

1

 

n i12

12

10

 

n i24

13

13

 

n t

22

14

Infliximab AS (n = 15)

n 0

2

2

 

n i12

8

3

 

n i24

11

4

 

n t

13

6

Control RA (n = 30)

n 0

5

0

 

n i12

4

2

 

n t

9

2

  1. ANA, antinuclear autoantibodies; anti-dsDNA, anti-double-stranded DNA autoantibodies; n0, number of positive sera before treatment; ni12, number of positive sera-induced autoantibodies after 12 months of treatment; ni24, number of positive sera-induced autoantibodies after 24 months of treatment; nt, number of positive sera before treatment plus number of induced autoantibodies during infliximab treatment.
Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us